CoChat

Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions

Open access
Hasib, Annie · 2020 · Clinical Medicine Insights: Endocrinology and Diabetes

The DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

The ever-increasing prevalence of obesity and Type 2 diabetes has necessitated the development of newer and more effective approaches for achieving efficient glycemic control and weight loss. Conventional treatment methods often result in weight gain, further deteriorating the already impaired metabolic control in people with obesity/Type 2 diabetes. Alleviation of obesity and diabetes achieved after bariatric surgeries highlight the therapeutic importance of gut-brain axis and entails development of more patient-friendly approaches replicating the positive metabolic effects of bariatric surgery. Given the potential involvement of several gut hormones in the success of bariatric surgery, the therapeutic importance of synergistic interaction between these hormones for improved metabolism cannot be ignored. Many unimolecular multiagonist peptides are in preclinical and clinical trials as they maximize the combinatorial metabolic efficacy by concurrent activation of multiple gut hormone receptors. This review summarizes the ongoing developments of multiagonist peptides as novel therapeutic approaches against obesity-diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1179551420905844

Cites

99 of 100 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. This scheme demonstrates how peptide/peptide multiagonist approaches offer beneficial metabolic profile by targeting multiple receptor pathways and can be harnessed as obesity and diabetes therapeutics. CCK indicates cholecystokinin; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like-peptide-1.
Figure 1. This scheme demonstrates how peptide/peptide multiagonist approaches offer beneficial metabolic profile by targeting multiple receptor pathways and can be harnessed as obesity and diabetes therapeutics. CCK indicates cholecystokinin; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like-peptide-1.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Research works printed but not linked: 3

  1. International Diabetes Federation, 2017, IDF Diabetes
  2. 10.1111/dom.12079 · DOI · Paper page
  3. 10.1007/s00125-018 · doi:10.1007/s00125-018

Cited by

See all 29

Metadata

Authors
Hasib, A.
Affiliations
University of Dundee (GB)
Corresponding author
Hasib, Annie
Venue
Clinical Medicine Insights: Endocrinology and Diabetes
Published
2020-01
Volume
13
Pages
117955142090584
ISSN
  • 1178-1173 (ISSN-L)
  • 1179-5514
OpenAlex
W3006226784
Cited by
29
References
98
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 11 · 2020: 3
FWCI
0.76
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Clinical Medicine Insights Endocrinology and Diabetes (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
obesity, type 2 diabetes, gastrointestinal hormones, gut-brain axis, peptide agonists, glycemic control, weight loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions. https://app.cochat.ai/papers/10.1177/1179551420905844
The paper
Hasib, A. (2020). Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions. Clinical Medicine Insights: Endocrinology and Diabetes. https://doi.org/10.1177/1179551420905844

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.